This retrospective observational cohort study examined serum fatty acid-binding protein 4 (FABP4) dynamics in 28 adults who underwent Roux-en-Y gastric bypass (RYGB), followed at baseline, 3 months, and 6 months. Anthropometric, metabolic, and inflammatory parameters were assessed alongside FABP4, fasting GLP-1, and PYY. Patients were classified as FABP4 responders (decrease from baseline to 6 months) or rebound/non-responders. The study investigated whether FABP4 trajectory after RYGB is associated with the magnitude of weight loss, systemic inflammation, and fasting incretin change.
Sixteen of the 28 participants had previously been enrolled in the control (probiotic-only, non-prebiotic) arm of a completed, registered randomized trial of pre-/probiotic supplementation after RYGB at the same institution (ClinicalTrials.gov Identifier: NCT03517345); these participants received no prebiotic intervention. The remaining 12 participants underwent RYGB by the same surgeon during a comparable period and were not enrolled in that trial. Blood samples from both subgroups had originally been collected and stored at -80°C as part of their respective prospective clinical follow-up. FABP4 concentrations were subsequently measured in these banked, single freeze-thaw samples using a commercial ELISA assay, blinded to patients' weight-loss and inflammatory outcomes, and merged with the anthropometric and biochemical data collected at the corresponding original visits. Because FABP4 assay and the present statistical analysis were performed after clinical follow-up had already been completed for both subgroups, this study is registered retrospectively.
Study Type
OBSERVATIONAL
Enrollment
28
Measure: Change in serum FABP4 level from baseline to 6 months after RYGB
Description: FABP4 measured by ELISA; patients classified as responders (decrease) vs. rebound/non-responders (no decrease or increase)
Time frame: Time Frame: Baseline, 3 months, 6 months
Change in BMI from baseline to 3 and 6 months
Change in BMI from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in body weight from baseline to 3 and 6 months
Change in body weight from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in fat mass (bioelectrical impedance) from baseline to 3 and 6 months
Change in fat mass and fat-free mass (bioelectrical impedance) from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in fat-free mass (bioelectrical impedance) from baseline to 3 and 6 months
Change in fat mass and fat-free mass (bioelectrical impedance) from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in HOMA-IR from baseline to 3 and 6 months
Change in HOMA-IR from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in IL-6 from baseline to 3 and 6 months
Change in hsCRP and IL-6 from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in hsCRP from baseline to 3 and 6 months
Change in hsCRP and IL-6 from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in fasting GLP-1 from baseline to 3 and 6 months
Change in fasting GLP-1 and PYY from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Change in fasting PYY from baseline to 3 and 6 months
Change in fasting GLP-1 and PYY from baseline to 3 and 6 months
Time frame: Baseline, 3 months, 6 months
Baseline-Adjusted 6-Month Change in Body Mass Index (BMI) by FABP4 Response Group
6-month change in BMI (kg/m²) was compared between FABP4 responder and rebound (non-responder) groups using an ANCOVA model adjusted for baseline (preoperative) serum FABP4 concentration (log-transformed). FABP4 response group was defined by the direction of change in serum FABP4, measured by enzyme-linked immunosorbent assay (ELISA), from baseline to 6 months after Roux-en-Y gastric bypass.
Time frame: Baseline, 3 months, 6 months
Odds Ratios for Predictors of 6-Month FABP4 Rebound: Early (0-3-Month) BMI Change, Age, and Sex
Odds ratios (OR) with 95% confidence intervals were estimated using a multivariable logistic regression model to identify predictors of FABP4 rebound status at 6 months after Roux-en-Y gastric bypass. Covariates included early (0-3-month) percentage change in body mass index (BMI), age (years), and sex (male/female). FABP4 rebound was defined as an increase in serum FABP4 concentration, measured by enzyme-linked immunosorbent assay (ELISA), from baseline to 6 months postoperatively.
Time frame: Baseline, 3 months, 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.